KP Tissue (TSE:KPT) has released an update.
KP Tissue Inc. reported robust financial results with a record $1.9 billion in sales and a significant increase in Adjusted EBITDA for the fiscal year 2023, alongside a solid Q4 performance boasting a 37.9% rise in Adjusted EBITDA and a slight increase in net income. The company’s growth was fueled by market share gains in the Consumer segment, strategic investments, and operational efficiency. KP Tissue is poised to continue this momentum into 2024, expecting stable margins and sustained EBITDA in Q1.
For further insights into TSE:KPT stock, check out TipRanks’ Stock Analysis page.
